Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | XBP1 | P17861 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17138201 | 0.95 | PRSS1 (0.43) | L3MBTL1GAAXBP1ATMNPSR1 | |
| SCHEMBL17138165 | 0.90 | TSHR (0.44) | L3MBTL1ALDH1A1TSHRMAPK1TDP1 | |
| SCHEMBL1537155 | 0.89 | CA2 (0.48) | L3MBTL1ATMALDH1A1CA2CYP3A4 | |
| SCHEMBL26566774 | 0.84 | LMNA (0.50) | ALDH1A1CYP3A4TSHRKMT2AMEN1 | |
| SCHEMBL2291004 | 0.84 | PRSS1 (0.48) | L3MBTL1ATMALDH1A1CA2CYP3A4 | |
| SCHEMBL17138193 | 0.83 | KMT2A (0.47) | L3MBTL1ATMALDH1A1CYP3A4TSHR | |
| SCHEMBL2294692 | 0.83 | PRSS1 (0.50) | L3MBTL1ALDH1A1TSHRTDP1KMT2A | |
| SCHEMBL1900961 | 0.83 | PRSS1 (0.50) | L3MBTL1ALDH1A1TSHRTDP1KMT2A | |
| SCHEMBL11699133 | 0.83 | PRSS1 (0.50) | L3MBTL1ALDH1A1TSHRTDP1KMT2A | |
| SCHEMBL2294967 | 0.83 | PRSS1 (0.50) | L3MBTL1ALDH1A1TSHRTDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150283051-A1 | DERIVATIVE OF NOVEL POLYHYDROXY AROMATIC COMPOUND AND USE THEREOF | RNS CO.,LTD. (KR) | 2015-10-08 | — | — | US | disclosed |
| CN-103664591-A | Novel benzendiol derivative compound and cosmetic composition utilizing the same | ACT CO LTD | 2014-03-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150283051-A1 | DERIVATIVE OF NOVEL POLYHYDROXY AROMATIC COMPOUND AND USE THEREOF | HRH3, CBR3, H1-0 | L3MBTL1 2433/4885GAA 4138/4885XBP1 3610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.